Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$0.39
$0.39
$0.23
$2.83
$26.62M1.55943,490 shsN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$8.23
-14.9%
$10.15
$3.60
$11.99
$106.19M0.4442,823 shs32,633 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
BiomX Inc. stock logo
PHGE
BiomX
$0.45
-39.4%
$0.50
$0.34
$3.86
$11.52M1.41106,621 shs53,300 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.82
-4.0%
$3.12
$1.81
$26.96
$10.51M0.54133,279 shs110,526 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00%0.00%0.00%0.00%0.00%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
0.00%+1.83%+12.53%-1.71%+53.86%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
BiomX Inc. stock logo
PHGE
BiomX
0.00%-2.40%-2.40%-22.76%-87.07%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
0.00%+7.38%-54.30%-69.12%-88.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.1561 of 5 stars
0.00.00.03.80.60.00.0
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
4.3338 of 5 stars
3.53.00.04.40.62.51.3
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.6709 of 5 stars
3.52.00.04.60.63.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00
N/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.00
Buy$12.0045.81% Upside
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00
N/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
3.00
Buy$21.004,587.50% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.333,885.31% Upside

Current Analyst Ratings Breakdown

Latest AGTC, XFOR, ERYP, PHGE, and CSBR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
BiomX Inc. stock logo
PHGE
BiomX
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$320K83.19N/AN/A$0.26 per share1.51
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$50.15M2.27N/AN/A($0.14) per share-58.79
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$32.66M3.24N/AN/A$0.80 per share3.88
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/A$0.70 per shareN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M4.11N/AN/A$3.90 per share0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$7.28M-$0.0617.66N/A10.97%656.65%24.04%N/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
-$240KN/A0.00N/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
-$28.32M-$0.85N/AN/AN/AN/A-127.82%-56.50%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.85N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest AGTC, XFOR, ERYP, PHGE, and CSBR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
N/AN/AN/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.39
1.40
1.40
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.99
0.99
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.32
3.65
3.65
BiomX Inc. stock logo
PHGE
BiomX
0.51
2.84
2.84
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
22.05%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.09%
BiomX Inc. stock logo
PHGE
BiomX
40.57%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
8367.63 million64.86 millionOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.83 million7.33 millionOptionable
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
4934.12 million33.46 millionNot Optionable
BiomX Inc. stock logo
PHGE
BiomX
12026.18 million44.04 millionNot Optionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.67 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Genetic Technologies stock logo

Applied Genetic Technologies NASDAQ:AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

ERYTECH Pharma stock logo

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

BiomX stock logo

BiomX NYSEMKT:PHGE

$0.45 -0.29 (-39.38%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.82 -0.08 (-3.97%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.